skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: My bank adviser recommended this fund. It has gone from $30 to $50 in the last 2 years. I see a MER of 3.10 and it has back end load.
Can you tell me how this back end load works in general and what you think of this fund? I wonder if there is a little bit of conflict of interest here because the bank sponsors this fund.
Read Answer Asked by Robert on February 05, 2016
Q: I would appreciate your opinion on Rockwell Medical (RMTI.US).
Is it buy at this level?
Thank you.

Milan
Read Answer Asked by Milan on February 04, 2016
Q: Would appreciate your opinion on MSL after acquisition news.
Some research puts fair value at $3.50 pre acquisition.
Thank you.
Read Answer Asked by Howard on February 03, 2016
Q: Gild has had a drop -- Pfe is more defensive (Div) . I am down sl. on PFE --thinking of switching. Concerned re the next drop ( MKT drop not over ) ---would you selll Pfe now & buy Gild at lower price. Or sell Pfe now & take a partial position --after Weds
--Div. day for pfe, Thank you-- great site . great insight
don
Read Answer Asked by Dr. Donald on February 02, 2016
Q: Could I please have your take on the latest news from this company and the new products they have acquired today?
Thank You
Garry
Read Answer Asked by garry on February 02, 2016
Q: "Yesterday there were two 500,000+ blocks at $6.60. We think the moves in the sector are entirely political worries, or sector rotation (into energy perhaps) but can't offer much more here. "


In your response to David's question I interpret it that someone(s) sold 2 blocks of 500K shares at $6.60.

I suggest it was someone(s) buying at a low. Especially considering it is rising now. I do not know if they were Black Pool buys.

Could these be viable possibilities?
Read Answer Asked by Stan (1) on January 29, 2016
Q: Hi again,

I have some IBB biotech etf which has followed the sector down. Do you see any positive potential for this sector over the next quarter or so?

Thanks
Read Answer Asked by Gary on January 29, 2016
Q: Hello.
Thanks for quality answers to questions.

Would you please help by offering insight to dealing with investor psychology and behaviour; 50% gain in PHM only to now be in the red on this holding?
My current thinking does not make sense to me to hold at the top of a gain only to feel like getting out now that the stock price has declined to the point that it feels like a poor investment decision.
I have been drawn into more aggressive type investments being connected to this subscription (beyond normal style) so I believe I can benefit from your experience and comments about dealing with volatility of the nature in this question.
Thanks
Dave

Read Answer Asked by David on January 29, 2016
Q: Re your answer is insider buying not worthy of a comment?
Read Answer Asked by j stuart on January 29, 2016
Q: i have been noticing a fairly large uptick in volume on knight over the last few days or weeks,normally it trades around 100k a day, but lately much more, maybe your bloomberg terminal give you more info than i can see.
also healthcare stocks across the board are selling off, concordia, knight, phm and even large biotechs in u.s. is this all because of hilary and u.s. election or something else. dave
Read Answer Asked by david on January 29, 2016
Q: Thoughts on CXR looking very attractively priced at the moment? They've got enough international exposure to their business that any action in the US to lower drug prices (which would likely take a new government and years to pass legislation) would not have a significant impact on CXR's business. Clinton's new video against Valeant and people panicking and selling CXR seem to be providing a great entry point.
Read Answer Asked by Arneh on January 29, 2016
Q: Many doctors are enthusiastic about GILD's hepatitis-C treatment which, while very, very expensive, is medically unusual for the high proportion of patients it actually cures (versus, many drug therapies are only incremental improvements on the therapies they supercede.) However - and aside from understandable friction over cost - is GILD potentially the victim of its drug's success: the more people they cure, the fewer customers they have remaining? And unlike, say, Apple (who is running out of new customers but can sell old customers an upgrade), cured patients have no reason to come back for more.
Read Answer Asked by John on January 28, 2016
Q: What are your thoughts on today's earnings? The market seems rather unimpressed.
Read Answer Asked by Brent on January 28, 2016
Q: I know its early yet but I would appreciate your researched insight into this game changing medical process and its potential as an investment.
Read Answer Asked by Ryczard on January 28, 2016
Q: i have been reading that beacon lowered the price target to a $1 and also i read about medicare reimbursement cuts which can negatively impact PHM ? Do you think PHM is still worth holding or should it be sold? What are your thoughts on this company?
Read Answer Asked by steven on January 27, 2016
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!